Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 3, 1996, Pages

  Cunningham, D ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

colorectal cancer; CPT 11 (irinotecan); MDR phenotype; topoisomerase I inhibitor

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ISOMERASE INHIBITOR;

ADJUVANT CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0029964872     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00290-0     Document Type: Review

References (39)

1. Cohen AM, Minsky BD, Schilsky RL. Colon Cancer. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th edition. Philadelphia, JB Lippincott, 1993, 929-977.
2. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993, 29A, 2077-2079.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122, 321-326.
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
5. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80, 30-36.
6. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12, 2640-2647.
7. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-755.
8. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992, 10, 904-911.
9. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
10. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
11. Leichmann CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
12. Adenis A, Bonneterre J, Pion JM, Degardin M, Horner D. Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer [correspondence]. Ann Oncol 1993, 4, 174-175.
13. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumour activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst 1971, 46, 789-795.
14. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970, 54, 461-470.
15. Creemers GJ, Lund B, Verweij J, et al. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994, 20, 73-96.
16. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991, 51, 4187-4191.
17. Tanizawa A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994, 86, 836-842.
18. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994, 34, 191-218.
19. Shimada Y, Rothenberg M, Hilsenbeck SG, et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994, 5, 202-206.
20. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988, 21, 71-74.
21. Chen AY, Yu C, Potmesil M, et al Camptothecin overcomes MDRl-mediated resistance in human KB carcinoma cells. Cancer Res 1991, 51, 6039-6044.
22. 2 every 3 weeks) in untreated non-small cell lung carcinomas [abstract], 8th European Conference on Clinical Oncology and Cancer Nursing (ECCO), Paris, 29 Oct-2 Nov 1995.
23. Chevallier B, Lhomme C, Dieras V, et al. A phase II study of CPT-11 (irinotecan) in chemotherapy naive patients with advanced cancer of the cervix uteri (C.C.U.) [abstract]. 8th European Conference on Clinical Oncology and Cancer Nursing (ECCO), Paris, 29 Oct-2 Nov 1995.
24. Wagener DJT, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995, 6, 129-132.
25. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992, 10, 16-20.
26. Fukuoka M, Niitani H, Taguchi T. Clinical study of CPT-11 in primary lung cancer [abstract]. 5th World Conference on Clinical Pharmacology and Therapeutics, Tokyo, 25 July 1992.
27. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10, 1225-1229.
28. Takeuchi S, Noda K, Yakushiji M. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma [abstract 708]. Proc Am Soc Clin Oncol 1992, 11, 224.
29. Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1991, 18, 1681-1689.
30. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1994, 21, 1033-1038.
31. Sakata Y, Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11), in advanced pancreatic cancer [abstract 633]. Proc Am Soc Clin Oncol 1993, 12, -.
32. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246, 1046-1048.
33. Hwang J, Shyy S, Chen AY, Juan CC, Whang-Peng J. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 1989, 49, 958-962.
34. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDRl (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87, 7160-7164.
35. Shimada Y, Rougier P, Pilot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996, 32A(Suppl. 3), S13-S17.
36. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996, 32A(Suppl. 3), S24-S31.
37. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996, 32A(Suppl. 3), S18-S23.
38. Wolmark N, Rockette H, Mamounas EP, et al. The relative efficacy of 5 FU + leucovorin (5FU-LV), 5 FU + levamisole (FU-LEV) in patients with Dukes' B and C carcinoma of the colon: first report of NSAPB C-04. Proc Am Soc Clin Oncol 1996, 460 (abstract).
39. Ota K, Ohno R, Shirakawa S, et al. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukaemia. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1994, 21, 1047-1055.